Litigation Details for Teva Pharmaceuticals International GmbH v. Eli Lilly and Company (D. Mass. 2018)
✉ Email this page to a colleague
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company (D. Mass. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-09-27 |
| Court | District Court, D. Massachusetts | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Allison Dale Burroughs |
| Jury Demand | Both | Referred To | |
| Patents | 8,586,045 | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
The biologic drug covered by the patent cited in this case is ⤷ Sign Up .
Details for Teva Pharmaceuticals International GmbH v. Eli Lilly and Company (D. Mass. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-10-17 | 535 | Memorandum & Order | 1 U.S. Patent Nos. 8,586,045 (the “’045 patent”); 9,884,907 (the “’907 patent”); and 9,884,908…alleging that Lilly has infringed three patents 1 (the “Patents-in-Suit”) that relate to the treatment… of the Patents-in- Suit to withhold any scientific references from the United States Patent & Trademark…presented to the Patent Trial and Appeals Board (“PTAB”) was the obviousness of the patents, which involved… here, the Patents-in-Suit “descend from, and claim priority to, two earlier parent patent applications | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
